Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04826133
Other study ID # 2000025367
Secondary ID
Status Terminated
Phase Early Phase 1
First received
Last updated
Start date March 27, 2019
Est. completion date January 17, 2020

Study information

Verified date August 2023
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to explore the effects of acute pre-treatment with 1,25-dihydroxyvitamin D3 (calcitriol), as compared to placebo on the behavioral (e.g., attempts to self-administer and ultimate number of infusions/boluses of cocaine self-administered), neurocognitive (e.g., performance on computerized tests of reward related learning such as the probabilistic selection task or PST and probabilistic reward task or PRT), and subjective effects (e.g, computerized visual analog scale [VAS] ratings of euphoria/, craving, etc.) of cocaine in experienced, non-treatment seeking users of the drug.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date January 17, 2020
Est. primary completion date January 17, 2020
Accepts healthy volunteers No
Gender All
Age group 30 Years to 55 Years
Eligibility Inclusion Criteria: - Age 30-55 years - Voluntary, written, informed consent - Physically healthy by medical history, physical, neurological, ECG and laboratory examinations - DSM-5 criteria for at least moderate Cocaine Use Disorder - Recent street cocaine use in excess of quantities used in the current study - Intravenous and/or smoked (crack/ freebase) use - Positive urine toxicology screen for cocaine - Laboratory evidence of vitamin D sufficiency (i.e., 25(OH)-vitamin D3 level = 20/mg) - For females, a negative serum pregnancy (HCG) test at screening and admission, and a negative urine pregnancy test (HCG) on cocaine administration days. Exclusion Criteria: - A history of other substance dependence (except for nicotine). Positive urine toxicology for cannabis is accepted for the study unless there is evidence for dependence per Structured Clinical Interview for DSM-5 (SCID) interview. Positive urine toxicology for other drugs at screening will be repeated. If positive again and/or positive at admission, subjects will be excluded - < 1 year of cocaine abuse/dependence - A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) unrelated to cocaine as determined by the SCID-5 - Medical comorbidities including serum calcium ( > 10.5 mg/dl, serum phosphorus > 4.2 mg/dl), hyperparathyroidism, kidney disease (e.g., Serum creatinine > 1.3 mg/dl) - A history of significant and uncontrolled medical (e.g., cardiovascular, diabetic/metabolic) or neurological (e.g., cerebrovascular, seizures, traumatic brain injury) illness - A history of seizures - Current use of psychotropic/potentially psychoactive medications or medications that can have drug drug interactions with calcitriol, including over the counter Vitamin D products, thiazide diuretics, and calcium supplements, etc, as referenced in the package insert for calcitriol - Seeking treatment for drug abuse/dependence - Hypersensitivity to calcitriol - For females, physical or laboratory (HCG) evidence of pregnancy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Calcitriol
Subjects will receive an oral administration of calcitriol (1,25-dihydroxyvitamin D3) 1.5 µg (three capsules of 0.5 µg each) at 9 pm, night before each cocaine session, and at 8 am, morning of each cocaine session. This dose of calcitriol is lower than doses safely administered in other human studies and for a duration of time shorter than doses safely administered in other trials. In addition, this dose has been already tested by our group, subject of a different grant application, and should be effective at enhancing stimulant's induced dopamine release, in comparison to placebo.
Other:
Placebo
Subjects will receive an oral administration of three capsules of placebo at 9 pm the night before each cocaine session, and at 8 am, morning of each cocaine session.

Locations

Country Name City State
United States Connecticut Mental Health Center New Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cocaine Self Administration Attempts Number of attempts to self administer cocaine will be analyzed. 90 minutes
Primary Cocaine Self Administration Infusions Number of infusions of cocaine will be analyzed. 90 minutes
Secondary Probabilistic Selection Task (PST) The Probabilistic Selection Task (PST) is a computerized task that assesses the tendency to learn from positive versus negative outcomes. PST will be analyzed using linear mixed models with treatment and time included as a within subjects variable. 15 minutes
Secondary Probabilistic Reward Task (PRT) The Probabilistic Reward Task (PRT) is a computerized task that uses an asymmetric reinforcement schedule to produce a response bias towards the more frequently rewarded of two possible stimuli. PRT will be analyzed using linear mixed models with treatment and time included as a within subjects variable. 15 minutes
Secondary Subjective Effects of Cocaine / Visual Analog Scale (VAS) During cocaine sessions, subjects will complete a series of self rated subjective effects measuring how they feel on cocaine, using a scale of 0 (not at all) to 10 (most ever). VAS ratings will focus on euphoria ("high") as a primary outcome, however, other positive, negative, psychomotor, and drug-craving ratings (e.g. good, bad, stimulated, paranoid, hungry, etc.) will be collected as well. Ratings are implemented on a touch-screen laptop computer and presented every 5 minutes, throughout the session 150 minutes
See also
  Status Clinical Trial Phase
Completed NCT03538548 - Treatment Outcome in CBT for Cocaine Use N/A
Recruiting NCT04994821 - tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study Phase 2
Not yet recruiting NCT06050304 - CRACK-TARGET 1: ÉTUDE DESCRIPTIVE DE LA SENSIBILISATION COMPORTEMENTALE OBSERVÉE et ATTENTES
Completed NCT02239913 - Topiramate-Phentermine Combinations for Cocaine Dependence Phase 1
Completed NCT02233647 - Phendimetrazine and Cocaine Early Phase 1
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Completed NCT03224546 - Cocaine Use Reduction and Health N/A
Recruiting NCT03656653 - Imagery-based Coping for Cocaine Use Disorder N/A
Completed NCT03348384 - [11C]NOP-1A and Cocaine Use Disorders Early Phase 1
Recruiting NCT05019430 - Cocaine and Zolmitriptan Early Phase 1
Recruiting NCT03344419 - Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders Phase 3
Recruiting NCT05507814 - Temporal Window and Episodic Future Thinking in CUD N/A
Active, not recruiting NCT03799341 - Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project N/A
Completed NCT02785406 - Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use Phase 2
Completed NCT02798627 - Trial Of NS2359 For The Treatment of Cocaine Dependence Phase 2
Completed NCT02444208 - A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use N/A
Recruiting NCT05902819 - Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories N/A
Recruiting NCT05833529 - Innovative Cognitive and Behavioral Psychotherapy for Cocaine Use Disorder N/A
Recruiting NCT05521854 - Contingency Management for Drug Use: Does Age Matter? N/A
Completed NCT05557149 - Virtual Reality Exposure and Respiratory Relaxation-Based Coping With Cocaine Craving in Cocaine Users N/A